姓名:刘健
职称:副教授
E-mail:liujian623@njucm.edu.cn
主要研究方向:药物分子设计与合成
个人简介
药物化学博士,副教授,硕士生导师。2015年博士毕业于复旦大学药物化学专业,同年9月进入717银娱geg优越会参加工作。目前,已获得国家自然科学基金青年基金、江苏省自然科学基金面上项目及青年基金、江苏省高校自然科学基金面上项目等基金资助,作为第二参与人参加国家自然科学基金--云南联合基金项目,入选江苏省第六期“333”第三层次人才。迄今在J. Med. Chem., Eur. J. Med. Chem., Org. Lett., Adv. Synth. Catal等SCI期刊上,以第一作者、通讯作者发表SCI论文30余篇, 申请中国专利3项,其中两项专利已与相关企业达成转让协议,里程碑式付款。担任JMC、EJMC等多个学术期刊的审稿人。
承担的主要科研项目
参考模板: 国家自然科学基金面上项目(项目编号),项目名称,2019/01-2022/12,主持(或参与),经费数,在研(或结题)
1.企业技术转让,炎性小体抑制剂PD-4-26的抗溃疡性结肠炎、痛风研究与开发,参与,在研,里程碑式付款已到账400
2. 国家自然科学基金云南联合基金重点项目(U2102201),强活性、高选择性的NLRP3炎症小体活化抑制剂去氢木香烃内酯的作用机制及其构效关系研究,2022/01-2025/12,参与,233万,在研
3. 江苏省自然科学基金面上项目(BK20211301),新型FGFR4蛋白降解剂的设计、合成及生物活性研究,2021/07-2024/06,主持,10万,在研
4. 国家自然科学基金青年基金项目(81703342),基于氨基酸突变耐药的新兴抑制剂的设计合成机制研究,2018/01-2020/12,主持,20.1万,已结题
5. 江苏省自然科学基金青年基金项目(BK20161050),针对“卡口残基”突变的新型FGFR抑制剂设计、合成及生物活性研究,主持,2016/07-2019/06,20万,已结题
6. 江苏省高校自然科学基金面上项目(16KJB350003),新型吲唑类FGFR抑制剂的结构优化及生物活性研究,2016/09-2018/06,主持,3万,已结题
代表性论文
Ping Wang#, Hongqiong Yang#, Weijiang Lin#, Jingxian Zhou, Yi Liu, Lingyu Ma, Mengting Li, Yang Hu, Chengli Yu, Yinan Zhang, Qi Lv *, Jian Liu*, Lihong Hu *. Discovery of Novel Sesquiterpene Lactones Derivatives as Potent PKM2 Activators for the Treatment of Ulcerative Colitis. Journal of Medicinal Chemistry, 2023, 66 (8): 5500-5523.
Huijuan Luo#, Dongjuan Si#, Xinjie Sun, Mengyun Wang, Yaobin Yang, Bo Wang, Hongmei Wen*, Wei Li*, Jian Liu*. Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer. European Journal of Medicinal Chemistry, 2023, 252, 115282.
Rupeng Dai#, Xueting Bao#, Ying Zhang, Yan Huang, Haohao Zhu*, Kundi Yang, Bo Wang, Hongmei Wen*, Wei Li*, Jian Liu*. Hot-Spot Residue-Based Virtual Screening of Novel Selective Estrogen-Receptor Degraders for Breast Cancer Treatment. Journal Chemical Information and Modeling. 2023, 63, 23, 7588-7602.
Xiaomeng Zhang#, Yazhou Wang#, Jianfeng Ji#, Dongjuan Si, Xueting Bao, Zhuangzhuang Yu, Yueyue Zhu, Liwen Zhao*, Wei Li*, Jian Liu*.Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma.Journal of Medicinal Chemistry, 2022 ,65 (11), 7595-7618.
Dongjuan Si#, Huijuan Luo#, Xiaomeng Zhang, Kundi Yang, Hongmei Wen, Wei Li*, Jian Liu*.Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors. Bioorganic Chemistry, 2021,115,105268
Xiaomeng Zhang#, Yazhou Wang#, Xue Li, Jie Wu, Liwen Zhao*, Wei Li*, Jian Liu*. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 11, 7575-7595.
Chao Wang#, Xiyan Rui#, Dongjuan Si, Rupeng Dai, Yueyue Zhu, Hongmei Wen, Wei Li*, Jian Liu*. Copper-Catalyzed Three-Component Cascade Reaction of Benzaldehyde with Benzylamine and Hydroxylamine or Aniline: Synthesis of 1,2,4-Oxadiazoles and Quinazolines.Advanced Synthesis & Catalysis, 2021,363, 2825-2833.
Jian Liu#, Yi Gao#, Yehua Zhu, Junru Zhu, Chao Wang, Xiyan Rui, Kundi Yang, Dongjuan Si, Jiamin Lin, Dandan Yuan, Hongmei Wen, Wei Li*. Rhodium(III)-Catalyzed Oxidative Annulation of 4-Aminoquinolines and Acrylate through Two Consecutive C(sp2)-H Activations. Organic Letters, 2020, 22(7): 2657-2662.
Jian Liu *, Jingxian Zhou #, Fengjun He #, Liang Gao, Yu Wen, Lina Gao, Ping Wang, Di Kang*, Lihong Hu*. Design, Synthesis and Biological Evaluation of Novel Indazole-Based Derivatives as potent HDAC Inhibitors via Fragment-Based Virtual Screening. European Journal of Medicinal Chemistry, 2020, 192, 112189.
Jian Liu *, Yu Wen #, Lina Gao #, Liang Gao, Fengjun He, Jingxian Zhou, Junwei Wang, Rupeng Dai, Xiaojing Chen, Di Kang *, Lihong Hu *. Design, Synthesis and Biological Evaluation of Novel 1H-1,2,4-Triazole, Benzothiazole and Indazole-Based Derivatives as potent FGFR1 Inhibitors via Fragment-Based Virtual Screening. Journal of Enzyme Inhibition and Medicinal Chemistry., 2020, 35, 72-84.
其他成果
胡立宏, 刘健, 吕祁, 胡杨, 王平, 董董, 杨梦. 愈创木烷类倍半萜衍生物及其制药用途. 授权日期:2024-1-26, 授权号:ZL202210573181.1
胡立宏,吕祁,刘健,胡杨,王平,董董,杨梦. 愈创木烷类倍半萜前药及其用途. 授权日期:2024-2-6, 授权号:ZL202210574929.X
胡立宏, 吕祁, 刘健, 张毅楠, 胡杨, 王平, 邢瑶. 二氢黄酮苷衍生物在制备防治结肠炎的药物中的用途. 授权日期:2023-11-28, 授权号:ZL202110210470.0
胡立宏, 刘健, 康迪, 王平, 崔珍珍, 孙玉, 林伟江. 愈创木烷型倍半萜衍生物在制备抗肿瘤药物中的应用.申请日期:2023-11-24, 申请号:202311592223.7
胡立宏,刘健,吕祁,林伟江,王平,王娟,谢颖. 一种愈创木烷型倍半萜内酯衍生物及其制法和应用. 申请日期:2023-11-24, 申请号:202311579631.9